[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 274
Citations 0
Comment & Response
February 2015

The Value of Pharmacogenetic Testing—Reply

Author Affiliations
  • 1Department of Medicine (Cardiology), University of California, San Francisco
  • 2Department of Epidemiology and Biostatistics, University of California, San Francisco
  • 3Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California
  • 4Department of Medicine, Stanford University School of Medicine, Stanford, California
JAMA Intern Med. 2015;175(2):314-315. doi:10.1001/jamainternmed.2014.7023

In Reply We thank Dr Pocinki for sharing his experience with pharmacogenetic testing over the past year. He notes that “with the exception of specific warfarin testing,” pharmacogenetic testing in his patient population has improved clinical decision making and patient outcomes. He cites his experience treating a young woman with chronic pain and “NSAID [nonsteroidal anti-inflammatory drug] intolerance” in whom pharmacogenetic testing showed to be a poor metabolizer of almost all NSAIDs, but suggested she could be treated with naproxen, which is metabolized by a different pathway. Dr Pocinki concludes that “waiting for the results of future, well-designed, adequately powered studies needlessly condemns countless patients to experience avoidable adverse reactions and treatment failures.”